An Unexpected Tumor Reduction: Treatment with Olaparib Monotherapy in Heavily Pretreated BRCA2 Mutated Metastatic Pancreatic Cancer

An Unexpected Tumor Reduction: Treatment with Olaparib Monotherapy in Heavily Pretreated BRCA2 Mutated Metastatic Pancreatic Cancer

PARP inhibitors are largely recognized as active drugs in BRCA-mutated breast and ovarian malignancies. In pancreatic ductal adenocarcinoma, the PARP inhibitor olaparib has recently been approved as maintenance treatment in patients with germline BRCA mutations reaching disease control after a plati...

Full description

Bibliographic Details
Main Authors: Alessandra Anna Prete, Letizia Procaccio, Francesca Bergamo, Cosimo Rasola, Floriana Nappo, Vittorina Zagonel, Sara Lonardi
Format: Article
Language:English
Published: MDPI AG 2022-01-01
Series:Current Oncology
Subjects:
olaparib
metastatic pancreatic cancer
BRCA
PARP inhibitors
Online Access:https://www.mdpi.com/1718-7729/29/2/49

Similar Items

Similar Items